Eli Lilly faces first U.S. trials over Cymbalta withdrawal

NEW YORK (Reuters) - Eli Lilly & Co on Tuesday will confront the first U.S. trial over allegations it failed to warn users of its popular antidepressant Cymbalta that they could suffer severe withdrawal symptoms, including suicidal thoughts and electric shock-like sensations.